Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TPST
TPST | US
2.39
USD0.08
3.46%
TPST | US
About TPST
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
2.39
Open
2.29
High
2.40
Low
2.28
Tempest Therapeutics Inc. a clinical-stage oncology company develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495 a dual antagonist of EP2 and EP4 receptors of prostaglandin E2 which is in a Phase 1 trial to treat solid tumors; and TPST-1120 a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1 a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics Inc. is headquartered in Brisbane California.
View LessTPST | US
Risk
47.3
Sharpe
-0.82
Luna's Score
37/100
Recommendation
Sell
Luna says (TPST | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
49.4%1 month
47.3%3 months
63.2%6 months
108.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.71
Debt to equity
1.20
Debt to assets
0.48
Ent. to EBITDA
0.31
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-31.25M
MarketCap
60.25M
MarketCap(USD)
60.25M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-289.26
Short ratio
5.12
Short perc.
8.91
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.40
Range1M
0.40
Range3M
1.11
Volumes: Market Activity
Rel. volume
0.82
Price X volume
177.21K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.31 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.71 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 63.17 | 72.80 | Par |
| Debt to Equity | 1.20 | -1.23 | Expensive |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 60.25M | 3.66B | Emerging |
